Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PALI with free AI briefings, catalyst countdowns, and dilution alerts.

PALI · Palisade Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$113.6M Cash on Hand
35.2mo Cash Runway
Follow PALI by email Get an email when PALI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PALI, unsubscribe in one click. Privacy

📣 What PALI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Protease Inhibitor Formulation LB1148 Ileus Phase 3 · NCT05470387 Terminated
PALI-2108 Ulcerative Colitis (UC) Phase 2 · NCT07845487 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PALI holds $113.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.7M/quarter from operations, an estimated runway of 35.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PALI files for a raise →

👥 Who Owns PALI

Insiders 4.5% Institutions (154 holders) 95.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
RA Capital Management, L.P. Institution (13G, 5%+) 20,884,964 11.65% 2026-09-30
Soleus Capital Master Fund, L.P. Institution (13G, 5%+) 14,996,154 8.36% 2026-09-30
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 14,885,421 8.30% 2025-11-28
Ameriprise Financial, Inc. Institution (13G, 5%+) 14,567,993 8.13% 2026-09-30
Perceptive Advisors LLC Institution (13G, 5%+) 14,113,863 7.87% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 10,436,760 5.82% 2026-06-30
Octagon Capital Advisors LP Institution (13G, 5%+) 9,567,898 5.34% 2025-12-31
Franklin Resources, Inc. Institution (13G, 5%+) 9,163,990 5.11% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 8,995,805 5.02% 2026-09-30
John David Finley
CEO CFO, Director · +1.88M options
Insider 2,033,141 1.13% 2026-10-06
Mitchell Lawrence Jones
President & Chief Medical Officer · +908,249 options
Insider 1,683,757 0.94% 2026-10-06
Donald Allen Williams
Director · +185,734 options
Insider 1,593,294 0.89% 2026-10-01

Share count 179,277,820 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PALI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PALI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.